New and emerging therapies in infectious diseases

Dermatologic Clinics

Volumn 18, Issue 1, 2000, Pages 31-35

  Harris, Bryan D ^a   Adal, Karim A ^b   Tomecki, Kenneth J ^a  

^a Departments of Dermatology   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BCG VACCINE; CHICKENPOX VACCINE; CIDOFOVIR; DALFOPRISTIN PLUS QUINUPRISTIN; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; IVERMECTIN; LEVOFLOXACIN; LYME DISEASE VACCINE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TERBINAFINE; THALIDOMIDE; TROVAFLOXACIN; UNINDEXED DRUG; VALACICLOVIR;

BACTERIAL INFECTION; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MYCOSIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; VIRUS INFECTION;

EID: 0033957886     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70144-3     Document Type: Article

References (32)

1. H.H. Balfour Antiviral drugs N Engl J Med 340 1999 1255 1268
2. D. Baltimore C. Heilman HIV vaccines: Prospects and challenges Sci Am 1998 98 103
3. R. Barkwell S. Shields Deaths associated with ivermectin treatment of scabies [letter] Lancet 349 1997 1144 1145
4. W.R. Bell J.D. Chulay J.E. Feinberg Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204) Medicine 76 1997 369 380
5. H.M. Bryson C.M. Spencer Quinupristin-dalfopristin Drugs 52 1996 406 415
6. A. Carr K. Samaras S. Burton A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 1998 F51 F58
7. Center for Disease Control Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recommendations and Reports 45 RR-11 1996 1 36
8. C.S. Crumpacker Ganciclovir N Engl J Med 335 1996 721 729
9. E. Epstein How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data Arch Dermatol 134 1998 1551 1554
10. A.K. Gupta P. Adam Terbinafine pulse therapy is effective in tinea capitis Pediatr Dermatol 15 1998 56 58
11. S. Hammer K. Squires M. Hughes A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less N Engl J Med 337 1997 725 733
12. J. Hanissian Emerging herpes vaccines Infections in Medicine 14 1997 205 206 , 208–209, 247,
13. P. Haslett V.H. Freedman G. Kaplan The emerging role of thalidomide therapy in HIV-infected patients Infections in Medicine 14 1997 393 398 , 405–406,
14. W.L. Heyward K.M. MacQueen K.L. Goldenthal HIV vaccine development and evaluation: Realistic expectations AIDS Res Hum Retroviruses. 14 1998 S205 S210
15. J.W. Hiemenz T.J. Walsh Lipid formulations of Amphotericin B: Recent progress and future directions Clin Infect Dis 22 suppl 2 1996 S133 S144
16. J.M. Jacobson J.S. Greenspan J. Spritzler Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection N Engl J Med 336 1997 1487 1993
17. Karonga Prevention Trial Group Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi Lancet 348 1996 17 24
18. N.I. Letvin Progress in the development of an HIV-1 vaccine Science 280 1998 1875 1880
19. B.A. Lipsky C.A. Baker Floroquinolone toxicity profiles: A review focusing on newer agents Clin Infect Dis 28 1999 352 364
20. Lyme disease–United States, 1995 MMWR Morb Mortal Wkly Rep 45 1996 481 484
21. T.L. Meinking D. Taplin J.L. Hermida The treatment of scabies with ivermectin N Engl J Med 333 1995 26 30
22. S. Partida-Sanchez L. Favila-Castillo S. Pedraza-Sanchez IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment Int Arch Allergy Immunol 116 1998 60 66
23. th Annual Meeting of the Society for Healthcare Epidemiology of America, April 18–20, 1999, San Francisco
24. R. Raz D. Miron R. Colodner A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection Arch Intern Med 156 1996 1109 1112
25. L.H. Sigal J.M. Zahradnik P. Lavin A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease N Engl J Med 339 1998 216 222
26. T.L. Smith M.L. Pearson K.R. Wilcox Emergence of vancomycin resistance in Staphylococcus aureus N Engl J Med 340 1999 493 501
27. A.C. Steere U.K. Sikand F. Meurice Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant N Engl J Med 339 1998 209 215
28. S.E. Straus A. Wald R.G. Kost Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial J Infect Dis 176 1997 1129 1134
29. E. Tschachler P.R. Bergstresser G. Stingl HIV-related skin diseases Lancet 348 1996 659 663
30. R.J. Whitley D.W. Kimberlin B. Roizman Herpes simplex viruses Clin Infect Dis 26 1998 541 555
31. A. Wong-Beringer R.A. Jacobs B.J. Guglielmo Lipid formulations of amphotericin B: Clinical efficacy and toxicities Clin Infect Dis 27 1998 603 618
32. M.J. Wood S. Shukla A.P. Fiddian Treatment of acute herpes zoster: Effect of early (< 48 h) versus late (48–72 h) therapy with acyclovir and valaciclovir on prolonged pain J Infect Dis 178 suppl 1 1998 S81 S84